$1.72
+0.02 (+1.18%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CRIS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
13 interventional · 2 with posted results
Held by 2 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, MAVERICK CAPITAL LTD) · FINRA short interest 1.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesNCT07271667Cohort 1: Undetectable Measurable Residual Disease (uMRD) RateNon-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Emavusertib, Zanubrutinib | Chronic Lymphocytic Leukemia, B-cell Malignancies | 108 | Nov 2027 | ≤ 467 d | 2026-06-12 |
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)NCT03328078Part A: To determine the safety and tolerability of emavusertib as a monotherapy and in combination with ibrutinib: dose-limiting toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Emavusertib, Ibrutinib | Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma | 152 | Aug 2026 | ≤ 11 d | 2026-04-16 |
| Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)NCT04278768Determine Maximum Tolerated Dose (MTD) of emavusertib (CA-4948) monotherapy (Phase 1)Non-randomized · Open-label · Treatment | Phase 1/2 | Suspendedsponsor's stated reason: Dosing completed in all cohorts. Planning underway for potential additional patient cohorts. | Drug: Emavusertib, Venetoclax, Emavusertib | Acute Myelogenous Leukemia, Myelodysplastic Syndrome | 366 | 2026-04-01 | — | 2026-03-19 |
| Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor MalignanciesNCT04475523To determine the maximum tolerated dose of CI-8993Open-label · Treatment | Phase 1 | Completed | Drug: CI-8993 | Solid Tumor | 26 | 2023-05-19actual | — | 2023-10-27 |
| Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With LymphomaNCT01742988To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of oral fimepinostat (CUDC-907) in combination with venetoclax and rituximabNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: fimepinostat, Rituximab, venetoclax | Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Relapsed and/or Refractory Lymphoma, Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Double-hit Lymphoma (DHL), Triple-hit Lymphoma (THL), Double-expressor Lymphoma (DEL), High-grade B-cell Lymphoma (HGBL) | 106 | 2020-10-09actual | — | 2021-05-06 |
| A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and LymphomasNCT02812875The number of patients with a dose-limiting toxicity (DLT) in the first treatment cycleOpen-label · Treatment | Phase 1 | Completed | Drug: CA-170 | Advanced Solid Tumors or Lymphomas | 71 | 2020-05-07actual | — | 2020-06-26 |
| Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid TumorsNCT02307240To determine the safety and tolerability of oral CUDC-907 in subjects with advanced/relapsed solid tumorsOpen-label · Treatment | Phase 1 | Completed | Drug: CUDC-907 | Triple-Negative Breast Cancer, High-grade Serous Ovarian Cancer, Solid Tumors, NUT Midline Carcinoma | 43 | 2019-05-31actual | — | 2019-09-03 |
| Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC AlterationsNCT02674750results2022-04-27Objective Response Rate (ORR)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 2 | Completed | Drug: CUDC-907 | Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations | 70 | 2019-05-28actual | — | 2022-04-27 |
| Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or LymphomaNCT01908413To determine the maximum tolerated dose (MTD) and recommended Phase 2 (monotherapy) dose of oral CUDC-427 administered on a 14 days on/7 days off dosing schedule in subjects with advanced and refractory solid tumors or lymphomaOpen-label · Treatment | Phase 1 | Terminated | Drug: CUDC-427 | Lymphoma | 23 | Mar 2015actual | — | 2016-12-01 |
| Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck CancerNCT01384799The number of participants with adverse events.Open-label · Treatment | Phase 1 | Completed | Drug: CUDC-101, Cisplatin · Radiation: Radiation Therapy | Head and Neck Cancer | 12 | Sep 2013actual | — | 2018-02-22 |
| Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer PatientsNCT01702285Determine the maximum tolerated dose (MTD) and recommended Phase 2 dose of oral CUDC-101 in subjects with advanced and refractory solid tumorsOpen-label · Treatment | Phase 1 | Terminated | Drug: CUDC-101 | Cancer | 3 | Dec 2012actual | — | 2018-02-12 |
| A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer TumorsNCT01171924results2015-10-16Number of Participants With Adverse EventsRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: CUDC-101, CUDC-101 | Head and Neck Cancer, Liver Cancer, Breast Cancer, Gastric Cancer, Non-Small Cell Lung Cancer | 47 | Oct 2011actual | — | 2016-03-01 |
| A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid TumorsNCT00728793The highest dose level of CUDC-101 at which <33% of at least 6 or more subjects experiences a dose limiting toxicity.Open-label · Treatment | Phase 1 | Completed | Drug: CUDC-101 | Tumors | 25 | Apr 2010actual | — | 2018-02-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19